Thyroid Eye Disease (TED) Clinical Trials

viridian thyroid eye disease clinical trial tile
immunovant clinical studies for thyroid eye disease, TED
Tourmaline TED clinical study tile

amgen rare disease logo

RECRUITING: A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease.

TEPEZZA® (teprotumumab) Approved in Brazil for the Treatment of Active Thyroid Eye Disease (TED). The first international approval outside of the U.S.

FDA expands teprotumumab indication to include any thyroid eye disease duration, activity.

Research presented  at the American Society of Ophthalmic, Plastic, and Reconstructive Surgery annual meeting noted a decrease in eye muscle size for patients with TED who underwent treatment with TEPEZZA (TM), resulting in better eye movement and less double vision.



ACELYRIN is currently recruiting for a clinical study designed to evaluate lonigutamab in subjects with TED. Use this link to learn more.


viridian therapeutics

immunovant solutions for thyroid eye disease

Immunovant is presently recruiting for a TED clinical research study. Please use this link to learn more.

See “Understanding Thyroid Eye Disease” contributed by Immunovant.


Lassen Therapeutics is currently recruiting for 2 clinical trials evaluating a novel treatment for people with TED.

Phase 2 clinical trial exploring LASN01 as a potential treatment for people with active TED

Phase 1 clinical trial further exploring LASN01 in people with active TED or idiopathic pulmonary fibrosis (IPF)


Tourmaline Bio is currently enrolling in the spiriTED Study – A Phase 2b clinical study investigating study drug TOUR-006 in patients with TED. Please visit – or for more information.


sling therapeutics

Sling Therapeutics is now recruiting participants for a Phase 2b study to evaluate a new oral treatment for TED.